Also at the end of that ten-year period, the NIH licensed didanosine to Barr Laboratories under a non-exclusive license, and didanosine became the first generic anti-HIV drug marketed in the United States.
Kasneje so Samuel Broder, Hiroaki Mitsuya in Robert Yarchoan z Ameriškega inštituta za raka (NCI) ugotovili, da ddA in ddI "in vitro" zavirata podvojevanje virusa HIV, in so izvedli klinične raziskave, ki so pokazale, da izkazuje didanozin to delovanje tudi pri bolnikih.